Im Cindy, Li Nan, Moon Wonjong, Liu Qi, Morton Lindsay M, Leisenring Wendy M, Howell Rebecca M, Chow Eric J, Sklar Charles A, Wilson Carmen L, Wang Zhaoming, Sapkota Yadav, Chemaitilly Wassim, Ness Kirsten K, Hudson Melissa M, Robison Leslie L, Bhatia Smita, Armstrong Gregory T, Yasui Yutaka
School of Public Health, University of Alberta, Edmonton, Canada.
Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
J Bone Miner Res. 2021 Apr;36(4):685-695. doi: 10.1002/jbmr.4234. Epub 2020 Dec 30.
Childhood cancer survivors treated with radiation therapy (RT) and osteotoxic chemotherapies are at increased risk for fractures. However, understanding of how genetic and clinical susceptibility factors jointly contribute to fracture risk among survivors is limited. To address this gap, we conducted genome-wide association studies of fracture risk after cancer diagnosis in 2453 participants of European ancestry from the Childhood Cancer Survivor Study (CCSS) with 930 incident fractures using Cox regression models (ie, time-to-event analysis) and prioritized sex- and treatment-stratified genetic associations. We performed replication analyses in 1417 survivors of European ancestry with 652 incident fractures from the St. Jude Lifetime Cohort Study (SJLIFE). In discovery, we identified a genome-wide significant (p < 5 × 10 ) fracture risk locus, 16p13.3 (HAGHL), among female CCSS survivors (n = 1289) with strong evidence of sex-specific effects (p < 7 × 10 ). Combining discovery and replication data, rs1406815 showed the strongest association (hazard ratio [HR] = 1.43, p = 8.2 × 10 ; n = 1935 women) at this locus. In treatment-stratified analyses in the discovery cohort, the association between rs1406815 and fracture risk among female survivors with no RT exposures was weak (HR = 1.22, 95% confidence interval [CI] 0.95-1.57, p = 0.11) but increased substantially among those with greater head/neck RT doses (any RT: HR = 1.88, 95% CI 1.54-2.28, p = 2.4 × 10 ; >36 Gray only: HR = 3.79, 95% CI 1.95-7.34, p = 8.2 × 10 ). These head/neck RT-specific HAGHL single-nucleotide polymorphism (SNP) effects were replicated in female SJLIFE survivors. In silico bioinformatics analyses suggest these fracture risk alleles regulate HAGHL gene expression and related bone resorption pathways. Genetic risk profiles integrating this locus may help identify female survivors who would benefit from targeted interventions to reduce fracture risk. © 2020 American Society for Bone and Mineral Research (ASBMR).
接受放射治疗(RT)和具有骨毒性的化疗的儿童癌症幸存者骨折风险增加。然而,对于遗传和临床易感性因素如何共同影响幸存者骨折风险的了解有限。为了填补这一空白,我们对来自儿童癌症幸存者研究(CCSS)的2453名欧洲血统参与者进行了癌症诊断后骨折风险的全基因组关联研究,其中930例发生骨折,使用Cox回归模型(即事件发生时间分析),并对按性别和治疗分层的遗传关联进行了优先级排序。我们在来自圣裘德终身队列研究(SJLIFE)的1417名欧洲血统幸存者中进行了重复分析,这些幸存者中有652例发生骨折。在发现阶段,我们在女性CCSS幸存者(n = 1289)中确定了一个全基因组显著(p < 5 × 10 )的骨折风险位点16p13.3(HAGHL),有强有力的性别特异性效应证据(p < 7 × 10 )。结合发现和重复数据,rs1406815在该位点显示出最强的关联(风险比[HR] = 1.43,p = 8.2 × 10 ;n = 1935名女性)。在发现队列的治疗分层分析中,rs1406815与未接受RT暴露的女性幸存者骨折风险之间的关联较弱(HR = 1.22,95%置信区间[CI] 0.95 - 1.57,p = 0.11),但在头部/颈部RT剂量较高的女性中显著增加(任何RT:HR = 1.88(此处原文有误,应为1.88),95% CI 1.54 - 2.28,p = 2.4 × 10 ;仅>36 Gray:HR = 3.79,95% CI 1.95 - 7.34,p = 8.2 × 10 )。这些头部/颈部RT特异性的HAGHL单核苷酸多态性(SNP)效应在女性SJLIFE幸存者中得到了重复。计算机生物信息学分析表明,这些骨折风险等位基因调节HAGHL基因表达和相关的骨吸收途径。整合该位点的遗传风险概况可能有助于识别那些将从针对性干预措施中受益以降低骨折风险的女性幸存者。© 2020美国骨与矿物质研究学会(ASBMR) 。 (注:原文中部分数据格式表述可能有误,已在译文中注明)